FabiSpray⁚ A Nitric Oxide Nasal Spray for COVID-19 Treatment
FabiSpray is a nitric oxide nasal spray (NONS) developed by Glenmark Pharmaceuticals in partnership with SaNOtize Research n Development Corp. It was launched in India in February 2022 for the treatment of adult patients with COVID-19 who have a high risk of disease progression.
How FabiSpray Works
FabiSpray is designed to kill the SARS-CoV-2 virus in the upper airways. Nitric oxide has proven antimicrobial properties and has been shown to have a direct virucidal impact on the virus. The spray is administered directly into the nostrils‚ where it targets the virus in the nasal passages‚ preventing it from spreading further down the respiratory tract.
Dosage and Administration
The recommended dosage of FabiSpray is two sprays in each nostril‚ six times a day for seven days. It is essential to follow the instructions provided by your healthcare professional.
Effectiveness
Studies have shown that FabiSpray can significantly reduce viral load in COVID-19 patients. A study published in the Lancet Regional Health‚ South Asia‚ demonstrated that NONS administration in unvaccinated adult patients with co-morbid conditions reduced Covid-19 viral load by 93 to 97 percent.
Availability and Price
FabiSpray is available in India at a cost of Rs 850 for the entire treatment course.
Important Information
- FabiSpray is not a substitute for vaccination. It is designed as a treatment for individuals who are already infected with COVID-19.
- FabiSpray should only be used under the supervision of a healthcare professional.
- It is crucial to follow the recommended dosage and administration guidelines.
Conclusion
FabiSpray is a novel nitric oxide nasal spray that has shown promising results in treating COVID-19. However‚ it is essential to remember that it is not a cure and should be used in conjunction with other treatment methods as recommended by your healthcare provider.